Charlyn

Quick links to important sections

Charlyn

Treatment option: Asthma, Bronchospasm

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Charlyn

Charlyn is a prescription-only medication that functions as a powerful anti-inflammatory agent, containing the single active ingredient, Flunisolide. It is formally classified as a corticosteroid, placing it within the group of anti-inflammatory steroids that modulate the body's natural immune responses.

Property Description
Active ingredient Flunisolide (or Flunisolide hemihydrate)
Form Nasal spray (solution) or Inhalation aerosol
Pharmacological class Corticosteroid / Glucocorticoid
Common purpose Prophylactic management of inflammation
Origin Synthetic fluorinated steroid

What Type of Medication is Charlyn?

Charlyn is a recognized brand name for the synthetic fluorinated steroid Flunisolide, belonging to the powerful Glucocorticoid pharmacological class. This single-ingredient product is clinically recognized for its ability to target local inflammatory pathways. Its core function is derived from Flunisolide, which acts as a Glucocorticoid Receptor Agonist, signifying that it binds to specific receptors to exert its pronounced anti-inflammatory action. This mechanism allows it to prevent or suppress local inflammation.

Composition and Delivery Form

The sole active compound in Charlyn is Flunisolide (or its stable form, Flunisolide hemihydrate), provided as a single-ingredient product within a liquid solution. The drug is primarily supplied for localized delivery, utilizing either an intranasal preparation (nasal spray) or an oral inhalation aerosol (pressurized metered dose inhaler), ensuring the Flunisolide solution is directed to the affected membranes. The specific nasal formulation is often designed as an aqueous solution with excipients to facilitate effective dispersion onto the mucosal lining, a characteristic important for maintaining consistent tissue contact.

General Purpose: Prophylaxis and Maintenance

The general therapeutic purpose of Charlyn is to provide prophylactic therapy and maintenance treatment by controlling underlying inflammation, swelling, and irritation. By reducing the local inflammatory response, Flunisolide prevents the gradual escalation of chronic symptoms and helps to maintain clearer breathing passages over time. For instance, it is typically used for long-term management in patients requiring sustained control of airway or nasal inflammation, as it works by prevention, rather than providing immediate relief for sudden, acute symptom flare-ups.

What side effects are possible with Charlyn?

Possible side effects and safety information

Charlyn, which contains the corticosteroid Flunisolide, has an official safety profile categorized by regulatory authorities, highlighting both local and potential systemic effects.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency, with local reactions and headache being among the most frequently reported events in regulatory documentation.

Classification Examples of Officially Documented Effects
Common Nasal irritation (burning/stinging), epistaxis (nosebleed), pharyngitis (sore throat), headache, flu-like symptoms.
Uncommon Nausea, vomiting, dizziness, rash, pruritus (itching).

Systemic and Serious Safety Considerations

The safety profile is organized by System-Organ Class (SOC) in official labeling. While effects are predominantly local (affecting the Respiratory, Thoracic, and Mediastinal Disorders class), the potential for systemic absorption is documented.

Serious Adverse Reactions officially listed include rare immediate and delayed hypersensitivity reactions (e.g., angioedema, anaphylaxis) and local structural complications like nasal septal perforation.

Population and Contextual Safety Notes

Regulatory documents highlight safety patterns linked to duration and specific populations:

  • Long-Term Exposure: The risk of systemic effects, such as adrenal suppression (HPA axis suppression), glaucoma, cataracts, and reduced bone mineral density, is associated with prolonged use or use exceeding recommended doses.
  • Paediatric Safety: The potential for systemic corticosteroid effects necessitates that the growth and height of children receiving this medication should be monitored.
  • Safety Restrictions: Use requires caution in individuals with active or quiescent tuberculosis or untreated systemic fungal, bacterial, or viral infections.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Manifestations: Acute vs. Chronic Risk

Official regulatory documents state that acute overdose with Flunisolide is not expected to produce life-threatening symptoms. However, the primary risk associated with overexposure is due to chronic, high-dose administration, which can lead to systemic corticosteroid effects. The most significant physiological finding documented in this context is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression (low adrenal gland function). Clinical presentations of prolonged overexposure may include manifestations of Hypercorticism, such as thinning skin, easy bruising, and observable changes in body fat distribution. Pediatric patients are specifically noted in official labeling as potentially more susceptible to this risk of HPA suppression from sustained high-dose exposure. For acute overexposure, management is officially classified as symptomatic and supportive treatment, as no specific antidote is known.

Emergency Action Requirements

Official regulatory information explicitly mandates that individuals seek immediate medical attention or contact a poison control center for any suspected overdose. Urgent medical help must be sought by calling emergency services if the affected individual displays severe symptoms, including trouble breathing or loss of consciousness. When chronic HPA suppression is confirmed, the official procedural step is gradual dose reduction combined with HPA function monitoring.

Therapeutic Uses of Charlyn

What Charlyn Treats: Main Uses and Benefits

Charlyn, which delivers the corticosteroid Flunisolide, is commonly used to provide supportive relief and long-term management of conditions presenting with systemic or localized discomfort. Its application includes easing symptomatic discomfort across key therapeutic domains, such as seasonal allergic rhinitis, perennial allergic rhinitis, and the management of chronic asthma where symptoms may intensify temporarily.

The medication is relevant for managing symptom clusters that create noticeable interference with daily stability, such as persistent runny nose (rhinorrhea), frequent sneezing, and distracting nasal itching and congestion. The therapeutic approach contributes to improved comfort during periods of heightened symptoms by helping to manage symptoms related to inflammatory or irritative states, which may assist with maintaining functional stability and supports general well-being during symptomatic phases. This approach is applied when conditions produce significant symptomatic burden and when supportive relief over time is needed. It is generally relevant in clinical settings that involve recurrent or episodic manifestations.


Quick Fact: Supports Management of Nasal Congestion


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Charlyn

Populations for whom use is allowed (as stated in label):

  • Adults and children 6 years of age and older are eligible for use.

Populations for whom use is contraindicated:

  • Use is strictly prohibited in patients with documented hypersensitivity to any product ingredient.
  • The nasal formulation must not be used in the presence of an untreated localized infection involving the nasal mucosa.
  • The inhalation formulation is not indicated for the primary treatment of status asthmaticus or acute episodes of asthma.

Age-related eligibility rules:

  • Safety and efficacy have not been established in patients less than 6 years of age.
  • Clinical studies did not include sufficient numbers of patients aged 65 years and over to definitively determine if they respond differently compared to younger adults.

Condition-specific eligibility rules and restrictions:

  • Use is restricted until healing has occurred in patients with recent nasal surgery or trauma.
  • Use is cautioned, or avoided if possible, in patients with active or quiescent tuberculosis of the respiratory tract or untreated fungal, bacterial, or systemic viral infections.
  • Patients transferring from prolonged systemic corticosteroid therapy must be carefully monitored.

Pregnancy and lactation eligibility status:

  • Use during pregnancy is conditional and is assigned Pregnancy Category C (when classified). It is only permissible if the potential benefit justifies the potential risk. Caution should be exercised when administering to nursing women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Entity Details from Regulatory Documents
Medicinal product categories with documented interactions Strong inhibitors of Cytochrome P450 3A4 (CYP3A4) and Other Systemic Corticosteroids.
Specific interacting medicines (if explicitly listed) Ritonavir, Ketoconazole, and Cobicistat; Mifepristone; Prednisone.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction via CYP3A4 inhibition and Pharmacodynamic interaction via additive glucocorticoid effects.
Timing-based interaction rules (if applicable) None documented for mandatory dose separation.
Interaction-related restrictions Co-administration with strong CYP3A4 inhibitors is officially not recommended. Co-administration with Mifepristone is generally prohibited.

Interaction Classifications (High-Level)

Classification Type Regulatory Statement
Interaction severity classification (as defined in official documents) Interactions with strong CYP3A4 inhibitors are considered clinically significant.
Regulatory basis (EMA / FDA / etc.) Information derived from FDA DailyMed and authoritative NIH monographs.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with strong inhibitors of Cytochrome P450 3A4 (CYP3A4) is officially not recommended due to a documented pharmacokinetic interaction.
  • This inhibition of CYP3A4 is stated to reduce the clearance of Flunisolide, resulting in increased systemic exposure of the active compound.
  • Combining Flunisolide with other systemic or inhaled corticosteroids results in a pharmacodynamic interaction that produces an additive glucocorticoid effect.
  • The co-administration of Flunisolide with Mifepristone is a generally prohibited combination across the corticosteroid class due to the risk of severe systemic outcomes.
  • Regulatory labeling does not contain formal, documented restrictions or warnings regarding interactions with food, alcohol, or common herbal products.

Connection to the overall interaction profile (2–4 sentences):

Official regulatory documents define the interaction profile by requiring specific attention to substances that cause a pharmacokinetic interference through the CYP3A4 metabolic pathway. This interference leads to a documented reduction in Flunisolide clearance. Furthermore, the profile explicitly lists medicines, such as Mifepristone, that constitute a generally prohibited combination based on the potential for systemic risk.

Mechanism of Action

How Charlyn Works: Mechanism of Action

Flunisolide's primary mechanism involves activating the cytosolic Glucocorticoid Receptor (GR), initiating a genomic cascade where the receptor complex enters the nucleus to directly repress genes that produce pro-inflammatory mediators (like NF-kappa B products). This slow, genomic action fundamentally changes the cell's inflammatory programming, resulting in the long-term modulation of the tissue's physiological response.

As a consequence of gene activation, Flunisolide causes the synthesis of proteins that act as inhibitors of the PLA2 enzyme. By cutting off the Arachidonic Acid cascade at an early stage, the mechanism suppresses the formation of all downstream inflammatory messengers, including prostaglandins and leukotrienes, which ultimately reduces localized vascular leakage and cellular infiltration.

The necessity of the full genomic cascade—requiring gene transcription and new protein synthesis—means the anti-inflammatory effect is not immediate but instead builds up gradually over days to weeks. This mechanistic constraint necessitates continuous receptor engagement and renders the mechanism functionally unsuitable for addressing sudden, acute physiological events characterized by rapid smooth muscle contraction (e.g., immediate bronchospasm), due to the lack of immediate non-genomic smooth muscle receptor action.

Dosage and Administration Information

Charlyn, which contains the corticosteroid Flunisolide, is a controller medicine that must be used regularly for long-term management, as its effectiveness is dependent on consistent application and may take up to two weeks for full benefit. The usage protocol is defined by the specific formulation, which dictates the delivery route and dosing schedule, strictly for intranasal use or oral inhalation.

Official Administration and Dosing

Administration Route Standard Adult Starting Dose Maximum Total Daily Dose
Intranasal Spray 2 sprays in each nostril 2 times a day 8 sprays in each nostril
Oral Inhalation 160 mcg (2 inhalations) 2 times a day 640 mcg (8 inhalations)

Procedural and Time-Relationship Instructions

  • Device Preparation: Both the nasal spray and the oral inhaler require priming (releasing test sprays into the air) before initial use and if unused for a specified number of days (e.g., 5 days for the nasal spray or 14 days for the oral inhaler). Priming ensures the delivery of a precisely measured dose.
  • Frequency: The standard dosing frequency is twice daily, administered at regular intervals, often recommended to be about 12 hours apart for the inhalation aerosol. If a dose is missed, it should not be doubled, and the next dose should be taken at the regular time.
  • Technique: For the nasal spray, the tip should be aimed toward the outer side of the nose, avoiding the nasal septum. Following oral inhalation, patients should rinse their mouth with water and spit the water out, to complete the procedural steps.
  • Dose Adjustment: Once a therapeutic effect is established, the prescribed dose should be gradually reduced to the lowest amount necessary to maintain control.

Recent Clinical Evidence

Research evidence / Overview of studies for Charlyn


Evidence for use in Allergic Rhinitis (Hay Fever)

Research has examined Charlyn in the context of allergic rhinitis, a condition characterized by fluctuating or episodic manifestations often linked to environmental triggers. Studies conducted during periods of increased symptom activity have focused on outcomes related to physical discomfort, such as sneezing, runny nose, and itchy eyes.

The available evidence from randomized trials describes patterns observed in studies related to outcomes reflecting daily functioning or activity level. These findings were based on research exploring short-term symptom changes over defined time intervals. However, follow-up durations were limited in many of the studies, meaning that what happens outside of short-term use may not be fully understood.

The data show patterns related to how patients reported their experience when symptoms were measured. While some trials report how symptoms evolved in the observed populations, subgroup findings are uncertain, and the degree of change may vary significantly among individuals. Comparative evidence is lacking for many head-to-head comparisons against other available options.


Evidence for use in Chronic Hives (Urticaria)

Charlyn was studied for chronic hives, a condition involving periods of heightened symptoms such as itching and welts. Trials for this indication often applied in research contexts involving fluctuating or unstable symptoms. The primary focus was observed in studies on patient-reported outcomes describing perceived discomfort and the extent of the skin reaction.

Research has explored this product in conditions involving periods of heightened symptoms, and the findings were associated with outcomes linked to inflammatory or irritative states. Studies focused on episodes where symptoms became more noticeable. However, findings were mixed regarding the long-term patterns of stability and flare-ups.

Evidence is limited when considering the full spectrum of this condition, and data are still emerging regarding certain populations. Studies help show what has been observed so far, but research provides context but not individual predictions about how well Charlyn may address chronic hive symptoms over an extended duration.


Long-term studies and follow-up

This section will summarize what is currently known and what remains unknown about the effects of taking Charlyn over a long period. Research was observed in some studies that monitored outcomes related to systemic or functional imbalance over longer timeframes and explored the durability of symptom relief beyond the short-term trial period.

However, a key limitation is that long-term effects are not fully established, and there is limited information for long-term outcomes for many individuals. Research is ongoing to better understand the long-term profile of Charlyn. Long-term effects are not fully established, and there is limited information for long-term outcomes for many individuals.


Evidence in special populations

Charlyn was evaluated in specific groups where data for certain groups remain insufficient. For instance, sample sizes were modest in studies involving children and older adults compared to the main trial populations. Research explored the product in conditions marked by functional limitations where other existing conditions (comorbidities) may influence the results.

The current evidence contributes to understanding symptom patterns in these special populations, but the results apply only to the populations studied. Because subgroup findings are uncertain, more research is needed to determine how symptoms evolve in diverse patient groups.


What is still uncertain about Charlyn

The evidence landscape has specific areas where certainty remains low. Evidence quality varies across studies, leading to different interpretations of the findings. Some trials examining outcomes capturing phases of heightened symptom activity have reported inconsistent data.

This section synthesizes the areas where research is ongoing regarding observed responses over defined time intervals and outcomes reflecting daily functioning or activity level. Findings describe group patterns, not personal outcomes, and it is important to remember that study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Charlyn (FAQ)

Q: How quickly does Charlyn start working after the first use?

Studies and official information indicate that this medication is not used for immediate, acute relief. Initial symptomatic improvement is often noted within a few days after starting regular use. However, the full therapeutic benefit may require one to two weeks of continuous application to be fully established.

Q: What happens if I miss taking Charlyn for one day?

The full effectiveness of this medication depends on consistent, regular use. If a dose is missed, regulatory information states that the dose should not be doubled to make up for the missed one. Simply take the next dose at the regularly scheduled time to maintain consistent levels.

Q: Is it safe to use Charlyn while taking antibiotics?

Regulatory documents cite potential interactions with certain drugs, specifically strong inhibitors of an enzyme called Cytochrome P450 3A4 (CYP3A4), which can increase the amount of this medication in the body. The overall interaction profile does not contain a blanket warning against all antibiotics.

Q: Does Charlyn interact with common pain relievers like ibuprofen?

While official labeling does not document a formal interaction with all common non-steroidal pain relievers, it does note that combining this medication with Acetylsalicylic acid (Aspirin) may increase the risk of gastrointestinal irritation.

Q: Are there any herbal supplements that should be avoided while using Charlyn?

Regulatory documents generally do not provide formal, documented restrictions or warnings regarding co-administration with common herbal products. The focus for documented interactions is primarily on specific prescription drug categories, such as strong CYP3A4 inhibitors and other corticosteroids.

Q: How long after stopping Charlyn does its effect wear off?

The active compound has a relatively short half-life in the bloodstream, typically around one to two hours. However, since the therapeutic action involves a slow, anti-inflammatory process that builds up over time, the full clinical effect subsides gradually and is not immediate upon cessation.

Q: What are the most frequent minor side effects of Charlyn?

According to official documentation, the most frequently reported adverse events include headache and a noticeable aftertaste. Common local reactions also include nasal irritation/stinging and nosebleeds (epistaxis).

Q: Is Charlyn known to cause or worsen acne?

Yes, acne has been reported as a side effect. It is listed as a common dermatologic adverse reaction in official documents, with a frequency noted between 1% and 10% in clinical data.

Q: Can Charlyn be used by women who are breastfeeding?

Official product information states that caution should be exercised when administering this medication to women who are nursing.

Q: Why is Charlyn prescribed for conditions other than contraception?

Charlyn is a corticosteroid, not a sex hormone. Official indications for this medication include the maintenance treatment of asthma as a preventive therapy, and the treatment of nasal symptoms associated with seasonal or perennial rhinitis (hay fever or allergies).

Q: Does Charlyn cause weight gain or weight loss?

Weight gain has been reported as a common side effect, classified within the 1% to 10% frequency in the metabolic adverse reaction category. Less frequently, both unusual weight gain and weight loss have been noted.

Q: Can Charlyn affect my mood or cause emotional changes?

Official documents list irritability, depression, and moodiness as common psychiatric adverse reactions. These effects are classified within the 1% to 10% frequency range in clinical trial data.

Q: Are headaches a common side effect reported with Charlyn?

Yes, headache is listed as a very common adverse reaction in the official documentation. It was reported in up to 13.8% of patients during clinical trials.

Q: Can I take Charlyn if I have high blood pressure?

High blood pressure (hypertension) is listed in regulatory documents as a common cardiovascular adverse reaction, occurring in 1% to 10% of patients. However, the official label does not list pre-existing high blood pressure as a formal contraindication.

Q: Are there specific age limits for who can use Charlyn?

The medication is approved for adults and children 6 years of age and older. Regulatory information notes that clinical studies did not include sufficient numbers of patients aged 65 years and over to definitively determine if their response is different from that of younger adults.

Q: What happens when I stop taking Charlyn?

Patients who are transferring from prolonged systemic corticosteroid therapy must be carefully monitored. Abrupt cessation in this context carries a risk of adrenal insufficiency and possible withdrawal symptoms, which may include muscle pain, tiredness, or depression.

Q: Is there a link between Charlyn and changes in vision?

Yes, regulatory documents note a link to vision changes. Blurred vision is listed as an uncommon side effect. Additionally, systemic risks associated with the prolonged use of corticosteroids, like this medication, include the development of glaucoma and cataracts.

Q: Can Charlyn be used long-term, and what is the typical duration of use?

This medication is designed for long-term prophylactic management. However, official labeling advises that treatment should generally not be continued beyond three weeks if no significant improvement in symptoms is observed. The goal is to use the lowest effective dose for the shortest time needed to maintain control.

Q: Is it normal to have reduced bleeding while taking Charlyn?

Menstrual disturbances are listed as a common side effect in official documents, classified under genitourinary reactions. However, the specific occurrence of reduced bleeding or other changes is not detailed in the official side effect descriptions.

Q: Can Charlyn be used by individuals with a history of migraines?

Migraine is listed as a common nervous system side effect, with a 1% to 10% frequency in regulatory documents. While this is a potential effect, the official label does not list a pre-existing history of migraines as a formal contraindication.

Q: What should be done if vomiting or diarrhea occurs shortly after taking Charlyn?

Vomiting and diarrhea are listed as common side effects of the medication. The instruction for a missed dose advises that if a dose is skipped due to illness, the instruction is to skip the missed dose and return to the regular schedule, and not to double up on doses.

Q: Does taking Charlyn require regular follow-up appointments with a doctor?

Yes, official documents emphasize that it is important to have the treatment progress checked by a doctor at regular visits to monitor its effectiveness and check for any unwanted effects.

Q: How do the hormones in Charlyn influence the body's natural cycle?

Charlyn is classified as a corticosteroid, which acts as a powerful anti-inflammatory agent, not a sex hormone. Despite this, menstrual disturbances are listed as a common genitourinary side effect in official documents, suggesting a possible systemic influence on the natural cycle.

Q: What studies exist regarding Charlyn's use in younger adult populations?

Clinical studies have been conducted in adult patients as a primary group. Separate clinical data and special considerations are noted in regulatory documents for pediatric patients (6-14 years of age) and older adults (over 65 years).

Q: Is there a difference in effectiveness if Charlyn is taken at night versus in the morning?

Official instructions require the medication to be taken twice daily at regular intervals (e.g., 12 hours apart). One specific study found that administration at 10 PM resulted in a smaller degree of cortisol suppression compared to other times, but adherence to the prescribed 12-hour regimen is the required standard.

Q: Does Charlyn affect dental health or lead to gum issues?

While the label does not specifically cite gum disease, local side effects noted include oral moniliasis (a fungal infection in the mouth or throat) and pharyngitis (sore throat). If using the oral inhaler, instructions recommend rinsing the mouth with water and spitting it out after use to help mitigate these local effects.

How should Charlyn be stored and disposed of?

Charlyn must be stored strictly according to the regulatory instructions for maintaining product integrity and safety.

Storage and Handling Requirements

Classification Official Requirement
Temperature Store at room temperature, typically 15 C to 25 C (59 F to 77 F).
Prohibitions Do not freeze. Store away from direct light, excess heat, and moisture (e.g., not in the bathroom).
Packaging Keep the medicine in its original container, tightly closed, and the nasal spray container upright.
Child Safety Keep out of the reach of children and pets.

Disposal and Canister Safety

Discard the nasal spray or aerosol container after the marked number of sprays/inhalations has been used, even if liquid remains. The preferred method for discarding unused or expired product is via a drug take-back program. Do not puncture the aerosol canister, and do not throw it into a fire or incinerator, even when empty, as it is a pressurized container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Charlyn found in:

A-Z Index: